ArticleHepatology international2025

Sequential combination with ropeginterferon alfa-2b and anti-PD-1 treatment as adjuvant therapy in HBV-related HCC: a phase 1 dose escalation trial.

Albert Qin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.